Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
5/7/25 Daiichi (4568) Enhertu for HER2+ Breast Cancer Subscribers Only Subscribers Only Subscribers Only
5/4/25 Sylentis SYL1801 for Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology) Subscribers Only Subscribers Only Subscribers Only
5/1/25 Genmab (GMAB) Epkinly for Follicular Lymphoma (FL) Subscribers Only Subscribers Only Subscribers Only
4/30/25 GSK (GSK) Nucala Liquid Formulation for Chronic Obstructive Pulmonary Disease (COPD) Subscribers Only Subscribers Only Subscribers Only
4/26/25 Pfizer (PFE) Sasanlimab for Bladder Cancer Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
04/01/2025 Subscribers Only Subscribers Only Company - Divestment/Spinoff
04/05/2025 Subscribers Only Subscribers Only Trial Data - Other
04/24/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
05/08/2025 Subscribers Only Subscribers Only Trial Data - Updated Results
05/08/2025 Subscribers Only Subscribers Only Trial Data - Updated Results